Moderna Cancer Vaccine Trial Success, But Stock Faces Whiplash

Hindustan Times · stocks

Moderna's personalized cancer vaccine has shown promising results in a large trial, significantly reducing the risk of melanoma returning or death when combined with Merck's Keytruda. The vaccine, which uses mRNA technology, cut this risk by 42% compared to Keytruda alone, surpassing the 40% benchmark investors had set. Despite this scientific milestone, Moderna's stock experienced volatility, falling about 20% after data leaked. Analysts suggest the stock's current valuation may be too high, potentially pricing in success across multiple cancer types beyond melanoma.